

To,

Date: 23rd May, 2026

The Manager BSE Limited P. J. Towers, Dalal Street Mumbai-400001 (BSE Scrip Code: 544742)	The Manager, NSE Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai- 400051. (NSE Symbol: SAIPARENT)
---	---

Dear Sir/Madam,

Unit: Sai Parenterals Limited

Subject: Investors Press Release on the Standalone & Consolidated Audited financial results for the quarter and year ended 31.03.2026.

Pursuant to Regulation 30(6) of the SEBI (LODR) Regulations 2015, please find the enclosed herewith the Press Release on the Standalone & Consolidated Audited financial results for the quarter and year ended 31.03.2026.

The Investor Press Release may also be accessed on the website of the Company at <https://www.saiparenterals.com/>

Request you to kindly take the same on record.

Thanking you,

**Yours faithfully,
For Sai Parenterals Limited**

**Mr. Anil Kumar Karusala
Managing Director
(DIN- 01866646)**

Encl: As above

Robust performance driven by CDMO exports and Noumed (Australia) integration

SAI Parenterals Limited (SPL) (NSE: SAIPARENT; BSE: 544742), a global diversified pharmaceutical company with capabilities in research, development and manufacturing for regulated, emerging and domestic markets, has announced its audited financial results for the quarter and year ended March 31, 2026.

Q4 FY26 — Performance Highlights

Quarter ended March 2026 vs. Q4 FY25

Revenue ₹197.93 Cr vs ₹74.23 Cr +166.65%	Total Income ₹200.81 Cr vs ₹74.37 Cr +169.97%	Gross Profit ₹76.51 Cr vs ₹16.13 Cr +374.3%
EBITDA ₹28.97 Cr vs ₹6.21 Cr +366.79%	PAT ₹13.25 Cr vs ₹1.59 Cr +736.04%	EPS (INR) ₹4.02 vs ₹0.59 +581.4%

Full Year FY26 — Performance Highlights

Full Year FY26 vs. FY25

Revenue ₹380.99 Cr vs ₹158.50 Cr +140.37%	Total Income ₹389.51 Cr vs ₹159.14 Cr +144.78%	Gross Profit ₹147.29 Cr vs ₹65.29 Cr +125.6%
EBITDA ₹47.21 Cr vs ₹35.42 Cr +33.29%	PAT ₹14.37 Cr vs ₹9.87 Cr +45.52%	EPS (INR) ₹4.36 vs ₹3.71 +17.5%

** Results of FY25 exclude discontinued business operations

** Results of Q4 & FY 26 includes the consolidation of our new subsidiaries Australian, New Zealand and Singapore.

** Revenue excludes other Income

Consolidated Profit and Loss Account - Q4 & FY26						
Particulars	Q4 FY 26	Q4 FY 25	QoQ	FY 26	FY 25	YOY
Revenue	197.93	74.23	166.65%	380.99	158.50	140.37%
Other Operating Income	2.88	0.14		8.52	0.64	
Total Income	200.81	74.37		389.51	159.14	
Total COGS	124.30	58.24		242.22	93.85	
Gross Profit	76.51	16.13		147.29	65.29	
Gross Margin (%)	38.66%	0.30		38.66%	41.19%	
Employee Cost	12.22	3.30		29.28	13.09	
Other Expenses	35.32	6.62		70.8	16.78	
EBIDTA	28.97	6.21	366.79%	47.21	35.42	33.29%
EBIDTA Margin (%)	14.64%	8.36%		12.39%	22.35%	
Depreciation	8.18	1.50		16.85	8.20	
Other Income	0.10	0.10		0.11	0.05	
EBIT	20.89	4.81		30.47	27.26	
Finance Cost	8.40	2.57		18.43	11.91	
Profit Before Tax	12.49	2.24		12.04	15.35	
Tax	-0.76	0.65		-2.33	5.48	
PAT	13.25	1.59	736.04%	14.37	9.87	45.52%
PAT Margin %	6.70%	2.14%		3.77%	6.23%	
Minority Interest	-	-		-2.25	0.25	
Profit after Tax and Minority Interest	13.25	1.59		16.62	9.62	
Profit after Tax and Minority Interest (%)	6.70%	2.14%		4.36%	6.07%	
EPS (INR)	4.02	0.59		4.36	3.71	

** Results of FY25 excludes discontinued business operations

Financial & business highlights

Consolidated performance demonstrates scale and execution

- Q4FY26 **revenue** stood at ₹197.93 crores with **growth of 166.65%** on Q-o-Q basis; **EBITDA** stood at ₹28.97 crores with **growth of 366.97%** on Q-o-Q basis; **PAT** stood at ₹13.25 crores with **growth of 736.04%** on Q-o-Q basis;
- FY26 **revenue** stood at ₹380.99 crores with **growth of 140.37%** on Y-o-Y basis; **EBITDA** stood at ₹47.21 crores **with growth of 33.29%** on Y-o-Y basis; and **PAT** stood at ₹14.37 crores with **growth of 45.52%** on Y-o-Y basis

Standalone performance in FY26

- Standalone **revenue** stood at ₹164.99 crores for FY26 with growth of **30.65%** on Y-o-Y basis; **EBITDA** stood at ₹33.32 crores with growth of **22.63%** on Y-o-Y basis; **PAT** stood at ₹16.86 crores with growth of **63.61%** on Y-o-Y basis;
- Growth driven by deeper engagement with our customers in export markets

Acquisition of Australia-based Noumed pharmaceuticals Pty Limited

- Acquisition of 74.6% controlling stake on November 12, 2025
- Provides access to established customer relationships and a portfolio of 451 dossiers, strengthening our position in the Australian pharmaceutical market.
- State-of-the-art manufacturing facility under development in Adelaide, Australia
- Strengthens our strategy to build a vertically integrated pharmaceutical platform in Australia in FY28

Robust product pipeline for regulated and emerging markets

- We have added 88 product dossiers portfolio in regulated and emerging markets in FY26 and 5 product dossiers portfolio with TGA Australia by Noumed, reflecting the scale and pace of our execution
- 67 product dossiers are in the pipeline and will be commercialised in FY27, providing strong growth visibility for our exports

Successful IPO and growth capital raised

- Successfully completed IPO in March 2026 with a primary fund raise of ₹285 crore
- Listed on April 02, 2026
- Allocated ₹130 crores for capacity expansion and upgradation of our manufacturing facilities and establishment of new dedicated R&D centre in India

Project update

The Company is executing a capex program focused on capacity expansion and upgradation of our manufacturing facilities, greenfield expansion at Australia and establishment of new dedicated R&D centre. All the projects are expected to be completed by FY27. Key initiatives include:

1. Capacity Expansion and EU-GMP upgradation at our India facilities at a Capex of ₹118 Crores to support growth in complex injectable formulations, CDMO opportunities and regulated-market exports.
2. The Construction of Australia's largest and most modern pharmaceutical plant built with Capex of AUD 53 million, will enable backward integration for long-term CDMO contracts and supporting onshoring opportunities with global customers. Backed by AUD 20 million grant from Australian Federal Government, the facility remains on track for completion in Q4FY27.
3. Establishment of a dedicated R&D centre at a Capex of ₹18 crore to accelerate product development and dossier filings.

Commenting on the performance, Mr. Anil KK, Managing Director, stated:

"We are proud to report an outstanding year of growth, led by a strong finish by SAI and its subsidiaries. This quarter marks the full consolidation of all its subsidiaries following its acquisition in November 2025, we are pleased to inform that Q4FY26 revenue crossing ₹197.93 Cr — a 166.65% jump year-on-year — and full year FY26 revenue reaching ₹380.99 Cr — a 140.37% jump year-on-year.

More importantly, our profitability has improved dramatically, EBITDA grew 366.79% in Q4 and PAT surged 736% — clear evidence of the operating leverage in our model. For the full year, EBITDA grew 33.29% and PAT grew 45.52%. We remain committed to disciplined growth, margin improvement, and delivering sustained shareholder value in FY27 and beyond."



“Our business continues to be underpinned by a strong IP-led approach, with consistent additions of new dossiers across markets. Our CDMO revenue have surged by over 250% YoY, supported by the signing of new long-term contracts that provide strong visibility for sustained growth in the coming years. We remain excited by the increasing scale of our operations and the opportunities emerging from our ongoing capex-led expansion. With ongoing capex of ~₹440 crores expected to be completed in FY27, we believe the company is well positioned for the next phase of growth.

We target to achieve 750 crore revenue for FY27 and EBITDA margins by to 17%. The outlook is underpinned by long-term supply agreements, the commercialization of new dossiers, strategic contribution from Noumed, Australia and sustained momentum across our exports and CDMO segments.”

=====

About Sai Parenteral’s Limited

Established in 2001, Sai Parenteral’s Limited is a global IP-led pharmaceutical formulations company with operations in India and Australia. The Company operates manufacturing facilities in India for injectables and oral dosage forms and has an upcoming facility in Australia for oral dosage forms. Supported by strong in-house R&D capabilities, the Company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to customers in India, regulated and semi-regulated markets.

DISCLAIMER

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sai Parenteral's Limited will not be in any way responsible for any action taken based on such statements and discussions; undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For any further information, please contact:

Mr. Anil Kumar

Chief Financial Officer

Email: ir@saiparenterals.com

For updates and specific queries, please visit <https://www.saiparenterals.com/>